{"filing":{"accession_number":"0001645113-26-000063","cik":"0001645113","ticker":"NVCR","company_name":"NovoCure Ltd","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"nvcr-20260723.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000063/nvcr-20260723.htm"},"events":[{"id":19789,"run_id":17808,"accession_number":"0001645113-26-000063","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing NovoCure's Q2 2026 financial results. The filing explicitly states \"On July 23, 2026, the Company issued a press release announcing certain financial results for the quarter ended June 30, 2026\" under Item 2.02. The press release reports quarterly net revenues of $183.6 million (16% YoY growth), net loss of $15.7 million, and operational metrics including 5,128 total active patients. The disclosure includes consolidated statements of operations, balance sheets, and forward guidance for full-year 2026 revenue of $710-$725 million.","company_name":"NovoCure Ltd","ticker":"NVCR","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":18977,"accession_number":"0001645113-26-000063","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing NovoCure's Q2 2026 financial results. The filing explicitly states \"On July 23, 2026, the Company issued a press release announcing certain financial results for the quarter ended June 30, 2026\" under Item 2.02. The press release reports quarterly net revenues of $183.6 million (16% YoY growth), net loss of $15.7 million, and operational metrics including 5,128 total active patients. The disclosure includes consolidated statements of operations, balance sheets, and forward guidance for full-year 2026 revenue of $710-$725 million.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T11:01:48.650280+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18977,"accession_number":"0001645113-26-000063","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing NovoCure's Q2 2026 financial results. The filing explicitly states \"On July 23, 2026, the Company issued a press release announcing certain financial results for the quarter ended June 30, 2026\" under Item 2.02. The press release reports quarterly net revenues of $183.6 million (16% YoY growth), net loss of $15.7 million, and operational metrics including 5,128 total active patients. The disclosure includes consolidated statements of operations, balance sheets, and forward guidance for full-year 2026 revenue of $710-$725 million.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T11:01:48.650280+00:00","company_name":"NovoCure Ltd","ticker":"NVCR","filing_date":"2026-07-23"}]}